Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company Indoco Remedies announced Q4FY24 & FY24 results:
Q4FY24 Financial Highlights:
- During the Q4FY24, revenues of Indoco Remedies grew by 1.7% at Rs 4,351 million, as against Rs 4,280 million, same quarter last year.
- EBIDTA to net sales for the quarter is 13.2% at Rs 574 million, compared to 15.0% at Rs 642 million, same quarter last year.
- Profit After Tax to net sales is 8.6% at Rs 376 million, compared to 5.9% at Rs 254 million, same quarter last year.
FY24 Financial Highlights:
- For the year, revenues grew by 7.6% at Rs 17,619 million, as against Rs 16,381 million, same period last year.
- EBIDTA to net sales for the period is 14.6% at Rs 2,580 million, compared to 17.4% at Rs 2,849 million, same period last year.
- Profit After Tax to net sales is 6.6% at Rs 1,166 million, compared to 8.6% at Rs 1,414 million, same period last year.
Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.”
FAQ’s on Indoco Remedies Ltd Shares
